Cancer testis antigens A new paradigm for cancer therapy

Suri, Anil
Saini, Shikha
Sinha, Abhilasha
Agarwal, Sumit
Verma, Archana
Parashar, Deepak
Singh, Swarnendra
Gupta, Namita
Jagadish, Nirmala

^*Correspondence to: Anil Suri; Email: [email protected] Submitted: 05/07/12; Accepted: 05/08/12 http://dx.doi.org/10.4161/onci.20686

Cancer Microarray; Genes and Proteins Laboratory; National Institute of Immunology; New Delhi, India

Abbreviations: SPAG9, sperm-associated antigen 9; CT, cancer testis; JNK, c-Jun N-terminal kinase; CTLA4, cytotoxic T-lymphocyte antigen 4

OncoImmunology 1(7):p 1194-1196, October 2012.

Cancer immunotherapy is a promising field with limited success, also due to lack of tumor-specific targets. In our attempt of exploring novel biomarkers and immunotherapeutic targets against cancer, we have discovered a novel cancer testis antigen, SPAG9, in cancers of different histological origin and demonstrated its potential role in oncogenesis.